BostonGene Announces Daiichi Sankyo Collaboration and EHA Congress Presentations
BostonGene announced a strategic collaboration with Daiichi Sankyo to integrate AI-driven analytics into an ADC development program. The company also revealed six abstracts will be presented at the EHA 2026 Congress in Stockholm. The research showcases integrated multiomics and predictive modeling for blood cancer treatment optimization.
BostonGene, a developer of AI foundation models for tumor and immune biology, has announced a strategic collaboration with Daiichi Sankyo to accelerate drug development through AI-driven multimodal analytics. The company also revealed that six of its abstracts have been accepted for presentation at the European Hematology Association (EHA) 2026 Congress.
The collaboration with Daiichi Sankyo will integrate AI-driven translational intelligence into an antibody drug conjugate (ADC) development program. The goal is to deliver decision-ready insights that directly inform patient selection strategies, development prioritization, and translational positioning. According to BostonGene's Chief Medical Officer, the work is "focused on accelerating learning cycles, lowering the cost of uncertainty, and differentiating this medicine earlier by identifying where it will most likely benefit patients with cancer."
The platform generates digital twin representations from hundreds of thousands of multiomic and histopathologic patient profiles to identify biological signatures and efficacy-associated mechanisms that distinguish responders from non-responders. This deep molecular mapping will enable the collaboration to define unique molecular subgroups and benchmark the investigational medicine relative to approved treatments.
Separately, BostonGene announced that six abstracts will be presented at the EHA 2026 Congress in Stockholm, Sweden, from June 11-14. The presentations showcase how BostonGene's platforms integrate clinical, genomic, and immune data to uncover critical disease mechanisms in blood cancers. The research was conducted in collaboration with leading institutions including Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, the University of Miami, and UT MD Anderson.
An oral presentation will feature research on integrated multi-omic profiling to identify genomic subtypes associated with different outcomes after CAR-T therapy in large B-cell lymphoma. Using BostonGene's Lymphly classifier, researchers found the BN2 subtype emerged as a high-risk group with significantly inferior survival. Additional poster presentations will cover refinements to diffuse large B-cell lymphoma classification using TP53 loss and aneuploidy, risk-stratified patient selection in multiple myeloma for frontline treatment, and peripheral blood immunoprofiling to define immune states in multiple myeloma.
BostonGene is headquartered in Waltham, Massachusetts. The company's foundation model integrates genomic, transcriptomic, and immune data with clinical outcomes to generate actionable insights for biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction.